Shots:
- The P-II trial of obexelimab (250mg, SC, QW) vs PBO in RMS, met its 1EP with a 95% relative reduction in cumulative new Gd-enhancing T1 lesions over wks. 8 & 12, with near-complete suppression by wk. 8 sustained through wk. 12.
- Adjusted mean new lesions was 0.01 vs 0.23, only 2 vs 19 total lesions occurred over wks. 8 & 12, 97.2% pts were T1 lesion-free, & mean B-cell values remained within the normal range
- The 24wk. data showed a ~95% reduction in total GdE T1 lesions from baseline (0.87) to wk. 12 (0.08) & wk. 24 (0.04). Obexelimab also reduced serum NfL by 40%, lowered new &/or enlarging T2 lesions, & kept EDSS scores stable, indicating no disability progression
Ref: Globenewswire | Image: Zenas |Press Release
Related News: Zenas BioPharma Enters ~$2B Deal with InnoCare Pharma for Three Autoimmune Product Candidates
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
